Trial Profile

A proof of concept study of INVA8001

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 28 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs INVA 8001 (Primary)
Indications Eosinophilic gastroenteritis; Primary biliary cirrhosis; Primary sclerosing cholangitis; Systemic mastocytosis
Focus Adverse reactions; Proof of concept; Therapeutic Use
Sponsors Invea Therapeutics

Most Recent Events

28 Apr 2023 New trial record
26 Apr 2023 According to an Invea Therapeutics media release, INVA8001 will enter into the clinic for proof of concept trials in the first half of 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com